Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitazoxanide vs Vancomycin in CDAD
NCT00384527Phase 3Terminated
- Sponsor
- Romark Laboratories
- Start
- Dec 2006
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nitazoxanide in Clostridioides difficile infection (CDI) (2 arms), sponsored by Romark Laboratories. Primary endpoint: Clinical response (resolution of all symptoms of CDAD). Started Dec 2006; status: terminated.
02
Drugs
nitazoxanide
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT00384527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384527.